Xue-Li Bai

List of Publications by Year
in descending order

124 papers	4,834 citations	101543 36 h-index	123424 61 g-index
127 all docs	127 docs citations	127 times ranked	7956 citing authors

#	Article	IF	Citations
1	Randomized phase III study of sintilimab in combination with modified folfrinox versus folfrinox alone in patients with metastatic and recurrent pancreatic cancer in China: The CISPD3 trial.. Journal of Clinical Oncology, 2022, 40, 560-560.	1.6	9
2	Randomized phase II trial of neoadjuvant chemotherapy with modified FOLFIRINOX versus modified FOLFIRINOX and PD-1 antibody for borderline resectable and locally advanced pancreatic cancer (the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	2
3	Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. Journal of Experimental and Clinical Cancer Research, 2022, 41, 56.	8.6	20
4	Fate of Surgical Patients with Small Nonfunctioning Pancreatic Neuroendocrine Tumors: An International Study Using Multi-Institutional Registries. Cancers, 2022, 14, 1038.	3.7	2
5	Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors. , 2022, 10, e003982.		25
6	Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surgery and Nutrition, 2022, 11, 227-252.	1.5	55
7	Commentary on â€œThe tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinomaâ€. Hepatobiliary Surgery and Nutrition, 2022, 11, 288-291.	1.5	0
8	Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy. EBioMedicine, 2022, 78, 103958.	6.1	15
9	Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer. Frontiers in Oncology, 2022, 12, 862154.	2.8	7
10	Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy. EBioMedicine, 2022, 79, 103987.	6.1	9
11	Liver cancer heterogeneity modeled by in situ genome editing of hepatocytes. Science Advances, 2022, 8, .	10.3	15
12	Preliminary data of a prospective study on the safety and efficacy of donafinib combined with anti-PD-1 antibody as adjuvant therapy for patients with hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2022, 40, e16131-e16131.	1.6	3
13	TALENTop: A multicenter, randomized study evaluating the efficacy and safety of hepatic resection for selected hepatocellular carcinoma with macrovascular invasion after initial atezolizumab plus bevacizumab treatment.. Journal of Clinical Oncology, 2022, 40, TPS4175-TPS4175.	1.6	3
14	lncRNAâ€POIR promotes epithelialâ€“mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miRâ€182â€5p. Journal of Cellular Biochemistry, 2021, 122, 130-142.	2.6	28
15	Preoperative transarterial chemoembolization for barcelona clinic liver cancer stage A/B hepatocellular carcinoma beyond the milan criteria: a propensity score matching analysis. Hpb, 2021, 23, 1427-1438.	0.3	6
16	Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduction and Targeted Therapy, 2021, 6, 72.	17.1	191
17	A preoperative nomogram predicts prognosis of patients with hepatocellular carcinoma after liver transplantation: a multicenter retrospective study. BMC Cancer, 2021, 21, 280.	2.6	4
18	Fate mapping analysis reveals a novel murine dermal migratory Langerhans-like cell population. ELife, 2021, 10, .	6.0	18

#	Article	IF	Citations
19	Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells. Oncogene, 2021, 40, 3136-3151.	5.9	9
20	Glucose Metabolism: The Metabolic Signature of Tumor Associated Macrophage. Frontiers in Immunology, 2021, 12, 702580.	4.8	27
21	A female surgeonâ€™s thoughts on gender attributes in surgery. Hepatobiliary Surgery and Nutrition, 2021, 10, 370-372.	1.5	3
22	NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nature Communications, 2021, 12, 4536.	12.8	51
23	Induced phase separation of mutant NF2 imprisons the cGAS-STING machinery to abrogate antitumor immunity. Molecular Cell, 2021, 81, 4147-4164.e7.	9.7	51
24	Non-cytomembrane PD-L1: An atypical target for cancer. Pharmacological Research, 2021, 170, 105741.	7.1	19
25	A Seven-Gene Signature to Predict Prognosis of Patients With Hepatocellular Carcinoma. Frontiers in Genetics, 2021, 12, 728476.	2.3	5
26	Combined targeted therapy and immunotherapy for cancer treatment. World Journal of Clinical Cases, 2021, 9, 7643-7652.	0.8	5
27	Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease. Frontiers in Microbiology, 2021, 12, 761836.	3.5	21
28	Novel deep learning radiomics model for preoperative evaluation of hepatocellular carcinoma differentiation based on computed tomography data. Clinical and Translational Medicine, 2021, 11, e570.	4.0	11
29	Multiplex imaging reveals the architecture of the tumor immune microenvironment. Cancer Biology and Medicine, 2021, 18, 949-954.	3.0	3
30	Factors associated with failure of enhanced recovery after surgery program in patients undergoing pancreaticoduodenectomy. Hepatobiliary and Pancreatic Diseases International, 2020, 19, 51-57.	1.3	12
31	External validation of alternative fistula risk score (a-FRS) for predicting pancreatic fistula after pancreatoduodenectomy. Hpb, 2020, 22, 58-66.	0.3	28
32	Role of Collateral Venous Circulation in Prevention of Sinistral Portal Hypertension After Superior Mesenteric-Portal Vein Confluence Resection during Pancreaticoduodenectomy: a Single-Center Experience. Journal of Gastrointestinal Surgery, 2020, 24, 2054-2061.	1.7	6
33	Development of a Novel Multiparametric MRI Radiomic Nomogram for Preoperative Evaluation of Early Recurrence in Resectable Pancreatic Cancer. Journal of Magnetic Resonance Imaging, 2020, 52, 231-245.	3.4	58
34	Blocking PD-L1 for anti-liver cancer immunity: USP22 represents a critical cotarget. Cellular and Molecular Immunology, 2020, 17, 677-679.	10.5	17
35	The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer. Pancreatology, 2020, 20, 95-100.	1.1	32
36	Liver Transplantation for Alcohol-Related Liver Disease (ARLD): An Update on Controversies and Considerations. Canadian Journal of Gastroenterology and Hepatology, 2020, 2020, 1-6.	1.9	4

#	Article	IF	Citations
37	Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations. Frontiers in Oncology, 2020, 10, 590058.	2.8	5
38	Outcomes of liver transplantation using moderately steatotic liver from donation after cardiac death (DCD). Annals of Translational Medicine, 2020, 8, 1188-1188.	1.7	6
39	Evaluation of Intra-Tumoral Vascularization in Hepatocellular Carcinomas. Frontiers in Medicine, 2020, 7, 584250.	2.6	16
40	Deubiquitinating Enzyme: A Potential Secondary Checkpoint of Cancer Immunity. Frontiers in Oncology, 2020, 10, 1289.	2.8	4
41	Oncolytic virus combined with traditional treatment versus traditional treatment alone in patients with cancer: a meta-analysis. International Journal of Clinical Oncology, 2020, 25, 1901-1913.	2.2	6
42	The AKT-independent METâ€“V-ATPaseâ€“MTOR axis suppresses liver cancer vaccination. Signal Transduction and Targeted Therapy, 2020, 5, 122.	17.1	9
43	Reviving the role of MET in liver cancer therapy and vaccination: an autophagic perspective. OncoImmunology, 2020, 9, 1818438.	4.6	7
44	Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression. Frontiers in Immunology, 2020, 11, 2076.	4.8	17
45	Sphincter of Oddi laxity alters bile duct microbiota and contributes to the recurrence of choledocholithiasis. Annals of Translational Medicine, 2020, 8, 1383-1383.	1.7	14
46	Combinational therapy targeting the METâ€mTORâ€ROS loop disrupts mitochondrial autoregulatory machinery of liver cancer. Clinical and Translational Medicine, 2020, 10, e237.	4.0	3
47	Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy. Npj Precision Oncology, 2020, 4, 29.	5.4	11
48	Molecular Profilingâ€“Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges. Frontiers in Oncology, 2020, 10, 532403.	2.8	20
49	Construction of a human cell landscape at single-cell level. Nature, 2020, 581, 303-309.	27.8	695
50	Calreticulin couples with immune checkpoints in pancreatic cancer. Clinical and Translational Medicine, 2020, 10, 36-44.	4.0	15
51	Eating self for not be eaten: Pancreatic cancer suppresses self-immunogenicity by autophagy-mediated MHC-I degradation. Signal Transduction and Targeted Therapy, 2020, 5, 94.	17.1	11
52	Contrastâ€enhanced CT radiomics for preoperative evaluation of microvascular invasion in hepatocellular carcinoma: A twoâ€center study. Clinical and Translational Medicine, 2020, 10, e111.	4.0	53
53	Prediction of postoperative pancreatic fistula using a nomogram based on the updated definition. Annals of Surgical Treatment and Research, 2020, 98, 72.	1.0	13
54	Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement. Frontiers in Cell and Developmental Biology, 2020, 8, 152.	3.7	46

#	Article	IF	Citations
55	Oncolytic virotherapy in hepatoâ€bilioâ€pancreatic cancer: The key to breaking the log jam?. Cancer Medicine, 2020, 9, 2943-2959.	2.8	12
56	VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy. Journal of Hematology and Oncology, 2020, 13, 83.	17.0	118
57	Genomeâ€wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis. Molecular Oncology, 2020, 14, 1966-1977.	4.6	12
58	A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma. Hpb, 2020, 22, 795-808.	0.3	39
59	Carcinosarcoma of the pancreas: comprehensive clinicopathological and molecular characterization. Hpb, 2020, 22, 1590-1595.	0.3	7
60	Patient-derived xenograft model engraftment predicts poor prognosis after surgery in patients with pancreatic cancer. Pancreatology, 2020, 20, 485-492.	1.1	12
61	Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis. Hpb, 2020, 22, 821-832.	0.3	54
62	Intratumoral heterogeneity of hepatocellular carcinoma: From single-cell to population-based studies. World Journal of Gastroenterology, 2020, 26, 3720-3736.	3.3	32
63	USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity. Cancer Immunology Research, 2019, 7, 1580-1590.	3.4	94
64	ABO-Incompatible Adult Living Donor Liver Transplantation in the Era of Rituximab: A Systematic Review and Meta-Analysis. Gastroenterology Research and Practice, 2019, 2019, 1-16.	1.5	21
65	Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. British Journal of Cancer, 2019, 121, 786-795.	6.4	47
66	B7â€H5/<scp>CD</scp>28H is a coâ€stimulatory pathway and correlates with improved prognosis in pancreatic ductal adenocarcinoma. Cancer Science, 2019, 110, 530-539.	3.9	24
67	Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut, 2019, 68, 2019-2031.	12.1	230
68	Surgical management and outcome of grade-C pancreatic fistulas after pancreaticoduodenectomy: A retrospective multicenter cohort study. International Journal of Surgery, 2019, 68, 27-34.	2.7	11
69	Liver Transplantation from Voluntary Organ Donor System in China: A Comparison between DBD and DCD Liver Transplants. Gastroenterology Research and Practice, 2019, 2019, 1-7.	1.5	7
70	Probable sirolimus-induced rupture of arterial anastomosis after liver transplantation in a patient intolerant of tacrolimus. Hepatobiliary and Pancreatic Diseases International, 2019, 18, 398-400.	1.3	3
71	Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. Cancer Letters, 2019, 452, 237-243.	7.2	78
72	Surveillance and management for serous cystic neoplasms of the pancreas based on total hazardsâ€”a multi-center retrospective study from China. Annals of Translational Medicine, 2019, 7, 807-807.	1.7	6

#	Article	IF	Citations
73	A nomogram for prediction of posthepatectomy liver failure in patients with hepatocellular carcinoma. Medicine (United States), 2019, 98, e18490.	1.0	6
74	Association of Modifiedâ€FOLFIRINOXâ€Regimenâ€Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population. Oncologist, 2019, 24, 301.	3.7	21
75	Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer. Molecular Cancer Therapeutics, 2019, 18, 196-203.	4.1	61
76	Predicting surgical site infections using a novel nomogram in patients with hepatocelluar carcinoma undergoing hepatectomy. World Journal of Clinical Cases, 2019, 7, 2176-2188.	0.8	8
77	Development of a radiomics nomogram based on the CE-CT features to predict the survival of upfront resectable patients with pancreatic head cancer and suspected venous invasion.. Journal of Clinical Oncology, 2019, 37, e15760-e15760.	1.6	0
78	Pancreatic cancer: Assessment of neoadjuvant chemotherapy outcome based on radiomics of pretreatment computed tomography.. Journal of Global Oncology, 2019, 5, 56-56.	0.5	0
79	Pancreas-preserving management of grade-C pancreatic fistula and a novel bridging technique for repeat pancreaticojejunostomy: An observational study. International Journal of Surgery, 2018, 52, 243-247.	2.7	9
80	Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society. Surgery, 2018, 164, 1392.	1.9	0
81	Hypoxiaâ€inducible factorâ€1Î±/interleukinâ€1Î² signaling enhances hepatoma epithelialâ€“mesenchymal transition through macrophages in a hypoxicâ€inflammatory microenvironment. Hepatology, 2018, 67, 1872-1889.	7.3	216
82	Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression. World Journal of Gastroenterology, 2018, 24, 3500-3512.	3.3	58
83	Preoperative prediction of peripancreatic vein invasion by pancreatic head cancer. Cancer Imaging, 2018, 18, 49.	2.8	10
84	Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. Radiation Oncology, 2018, 13, 188.	2.7	67
85	Laparoscopic Spleen-Preserving Distal Pancreatectomy (LSPDP) with Preservation of Splenic Vessels: An Inferior-Posterior Approach. Gastroenterology Research and Practice, 2018, 2018, 1-7.	1.5	11
86	Tumor-derived exosomes promote tumor self-seeding in hepatocellular carcinoma by transferring miRNA-25-5p to enhance cell motility. Oncogene, 2018, 37, 4964-4978.	5.9	47
87	A preoperative nomogram predicts prognosis of up front resectable patients with pancreatic head cancer and suspected venous invasion. Hpb, 2018, 20, 1034-1043.	0.3	12
88	The role of imaging in prediction of post-hepatectomy liver failure. Clinical Imaging, 2018, 52, 137-145.	1.5	17
89	Primary tumor-derived exosomes facilitate metastasis by regulating adhesion of circulating tumor cells via SMAD3 in liver cancer. Oncogene, 2018, 37, 6105-6118.	5.9	119
90	Patients with pancreatic cystic neoplasms can benefit from management of multidisciplinary team: Experience from a Chinese academic center. Pancreatology, 2018, 18, 799-804.	1.1	8

#	Article	IF	Citations
91	Liquid biopsy in pancreatic cancer: the beginning of a new era. Oncotarget, 2018, 9, 26900-26933.	1.8	47
92	Salvage Liver Transplant versus Primary Liver Transplant for Patients with Hepatocellular Carcinoma. Annals of Transplantation, 2018, 23, 524-545.	0.9	20
93	Single tumor-initiating cells evade immune clearance by recruiting type II macrophages. Genes and Development, 2017, 31, 247-259.	5.9	207
94	Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population. Cancer Letters, 2017, 406, 22-26.	7.2	47
95	Hook1 inhibits malignancy and epithelialâ€“mesenchymal transition in hepatocellular carcinoma. Tumor Biology, 2017, 39, 101042831771109.	1.8	10
96	Hypoxia-inducible factor-2Î± promotes tumor progression and has crosstalk with Wnt/Î²-catenin signaling in pancreatic cancer. Molecular Cancer, 2017, 16, 119.	19.2	97
97	Pancreatic cancer adjuvant radiotherapy target volume design: based on the postoperative local recurrence spatial location. Radiation Oncology, 2016, 11, 138.	2.7	11
98	The implementation of an enhanced recovery after surgery (ERAS) program following pancreatic surgery in an academic medical center of China. Pancreatology, 2016, 16, 665-670.	1.1	31
99	ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelialâ€“mesenchymal transition. Cancer Letters, 2016, 377, 140-148.	7.2	40
100	Regulation of Multi-drug Resistance in hepatocellular carcinoma cells is TRPC6/Calcium Dependent. Scientific Reports, 2016, 6, 23269.	3.3	90
101	G protein-coupled estrogen receptor deficiency accelerates liver tumorigenesis by enhancing inflammation and fibrosis. Cancer Letters, 2016, 382, 195-202.	7.2	47
102	Meta-analysis of invagination and duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy: An update. International Journal of Surgery, 2016, 36, 240-247.	2.7	25
103	The hepatitis B virus X protein promotes pancreatic cancer through modulation of the PI3K/AKT signaling pathway. Cancer Letters, 2016, 380, 98-105.	7.2	38
104	Duct-to-Mucosa vs Invagination for Pancreaticojejunostomy after Pancreaticoduodenectomy: A Prospective, Randomized Controlled Trial from a Single Surgeon. Journal of the American College of Surgeons, 2016, 222, 10-18.	0.5	78
105	Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis. Cancer Research, 2016, 76, 818-830.	0.9	225
106	LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation. Tumor Biology, 2016, 37, 7277-7286.	1.8	12
107	One-stage laproendoscopic procedure versus two-stage procedure in the management for gallstone disease and biliary duct calculi: a systemic review and meta-analysis. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 3582-3590.	2.4	47
108	Roles of Sphincter of Oddi Laxity in Bile Duct Microenvironment in Patients with Cholangiolithiasis: From the Perspective of the Microbiome and Metabolome. Journal of the American College of Surgeons, 2016, 222, 269-280e10.	0.5	31

#	Article	IF	Citations
109	Characteristics of Tumor Infiltrating Lymphocyte and Circulating Lymphocyte Repertoires in Pancreatic Cancer by the Sequencing of T Cell Receptors. Scientific Reports, 2015, 5, 13664.	3.3	49
110	Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the Î²-catenin/TCF complex association via FOXO3a activation. Oncotarget, 2015, 6, 10350-10365.	1.8	84
111	Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells. Molecular Cancer Therapeutics, 2015, 14, 1805-1815.	4.1	36
112	WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation. Cancer Letters, 2015, 361, 218-225.	7.2	55
113	OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine bothin vitroandin vivo. Oncotarget, 2015, 6, 26230-26241.	1.8	18
114	Autologous bone marrow transplantation in decompensated liver: Systematic review and meta-analysis. World Journal of Gastroenterology, 2015, 21, 8697.	3.3	9
115	A Case Report on Successful Liver Transplantation from a Donor with Polycystic Liver. Indian Journal of Surgery, 2014, 76, 405-407.	0.3	0
116	Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1Î±-VEGF mediated angiogenesis. Cancer Letters, 2014, 355, 281-287.	7.2	44
117	Hypoxia-inducible factor 1Î± expression and its clinical significance in pancreatic cancer: A meta-analysis. Pancreatology, 2014, 14, 391-397.	1.1	57
118	Inhibition of Protein Phosphatase 2A Enhances Cytotoxicity and Accessibility of Chemotherapeutic Drugs to Hepatocellular Carcinomas. Molecular Cancer Therapeutics, 2014, 13, 2062-2072.	4.1	29
119	Pancreatic cystic neoplasms: a review of preoperative diagnosis and management. Journal of Zhejiang University: Science B, 2013, 14, 185-194.	2.8	15
120	Acute iatrogenic Budd-Chiari syndrome following hepatectomy for hepatolithiasis: A report of two cases. World Journal of Gastroenterology, 2013, 19, 5763.	3.3	7
121	Duct-to-mucosa versus invagination pancreaticojejunostomy after pancreaticoduodenectomy: a meta-analysis. Chinese Medical Journal, 2013, 126, 4340-7.	2.3	9
122	Sister Mary Josephâ€™s nodule as a first sign of pancreatic cancer. World Journal of Gastroenterology, 2012, 18, 6686.	3.3	18
123	Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2007, 134, 83-91.	2.5	73
124	Long-term results of laparoscopic fenestration for patients with congenital liver cysts. Hepatobiliary and Pancreatic Diseases International, 2007, 6, 600-3.	1.3	20